Hims & Hers Settles Patent Dispute with Novo Nordisk; Shares Jump 48.7%
Hims & Hers ended its patent dispute with Novo Nordisk to distribute semaglutide via its telehealth platform, lifting shares 48.7% in premarket. Q4 revenue of $617.8M slightly missed the $619.2M consensus while EPS jumped to $0.08 from $0.03, and Q1 revenue guidance of $600M–$625M trails the $653.1M forecast.
1. Legal Settlement and Partnership
Hims & Hers resolved patent infringement claims with Novo Nordisk, securing rights to distribute semaglutide-based weight-loss drugs through its telehealth platform under a new partnership agreement.
2. Q4 Financial Results
The company reported Q4 revenue of $617.8 million, narrowly missing the $619.2 million consensus, while EPS of $0.08 topped the $0.03 estimate. Management guided Q1 revenue between $600 million and $625 million and fiscal 2026 sales of $2.7 billion to $2.9 billion.
3. Stock Performance and Technicals
Shares surged 48.7% in premarket trading, trading 41.6% above the 20-day SMA but 30.4% below the 100-day SMA. An RSI near 30.9 and a bullish MACD crossover suggest potential upward momentum.
4. Analyst Ratings and ETF Exposure
Analysts from Barclays and Morgan Stanley cut price targets to $25 and $21 respectively, reflecting mixed sentiment. Hims & Hers accounts for 1.17% of the SPDR S&P 600 Small Cap Growth ETF (SLYG), indicating notable ETF interest.